Introduction
Non-Hodgkin's lymphoma is the second most frequent AIDS-defining cancer and is still the most frequent neoplastic cause of death among HIV-infected individuals [1] . Compared with immunocompentent individuals, HIV-infected patients have a higher risk of developing non-Hodgkin's lymphoma, particularly diffuse large Bcell lymphoma (DLBCL) [2] . The administration of combination antiretroviral therapy (cART) to HIVinfected individuals has improved the status of their immune system, as measured by CD4 þ lymphocyte counts. Consequently, the incidence of most HIV-related infections and neoplasms has decreased, including AIDSrelated lymphoma (ARL). However, changes in the incidence of ARL subtypes have been heterogeneous with a decrease in the incidence of lymphomas typically presenting in patients with advanced immunodeficiency [e.g., primary central nervous system (CNS) lymphoma and systemic DLBCL] and an increase in the incidence of lymphomas that occur in less immunosuppressed patients such as Burkitt's lymphoma and Hodgkin lymphoma [3] . The pathogenesis of HIV-related lymphomas has been linked to chronic antigen stimulation, coinfection with oncogenic viruses such as Epstein-Barr virus and human herpes virus-8, genetic abnormalities, and cytokine deregulation [4] . The antiviral effects and the improvement in immune function with the use of cART may have altered the action of these lymphomagenic stimuli, and hence changed some of the classical features of HIVrelated lymphomas. However, these features have been scarcely investigated and further studies are needed to define the clinical-biological features of patients with HIV-related DLBCL in the cART era.
The prognosis of HIV-related lymphomas has substantially improved with the introduction of cART, mostly because cART has reduced the risk of infectious complications preventing patient death from AIDS-related diseases other than lymphoma [5] . Additionally, the use of the granulocyte colony-stimulating factor has decreased the frequency of neutropenic-related infections and has contributed to timely administration of adequate systemic treatment [6] . Some studies on patients with DLBCL treated with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) have shown that the outcomes of HIV-infected patients are approaching those of HIV-uninfected patients [7] [8] [9] . The anti-CD20 antibody rituximab (R) is currently included in the chemotherapeutic regimens administered to HIV-infected patients and the most recent data support its use [10] [11] [12] . Although the prognosis of HIV-infected patients with DLBCL is better than in the pre-cART era, their characteristics and responses to R-CHOP therapy may still be different from those of non-HIV-infected patients.
Herein, we compared two series of patients with DLBCL treated with R-CHOP in order to ascertain differences in clinical presentation and outcome between HIV-uninfected and HIV-infected patients treated in the cARTera.
Methods

Patients
Two series of patients diagnosed with DLBCL and treated with R-CHOP were retrospectively studied. The first, consisted of 81 patients with HIV-related DLBCL enrolled in a phase II clinical trial of R-CHOP and cART conducted by the Spanish PETHEMA (Programa para el Estudio y Tratamiento de las Hemopatias Malignas), GESIDA (Grupo de Estudio de SIDA), GELTAMO (Grupo Español de Linfoma y Trasplante de Médula Ó sea), and GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear) groups [13, 14] . The trial was activated in April 2001 and closed for patient follow-up in October 2011. Administration of cARTwas required from the beginning of lymphoma treatment if patients were not already receiving it, and consisted of one or two protease inhibitors and two nucleoside reverse transcriptase inhibitors. The second series included 84 HIV-uninfected patients with DLBCL consecutively diagnosed and treated with R-CHOP in our institution between 2002 and 2010. The following clinical and biological parameters were collected from records: age, sex, date of lymphoma diagnosis, Eastern Cooperative Oncology Group (ECOG) score, hepatosplenomegaly, number and localization of extranodal sites, B symptoms, bulky disease, Ann-Arbor stage, complete blood counts, serum lactate dehydrogenase (LDH) levels, international prognostic index (IPI), type of response, response date, relapse date, death date, and cause of death. In HIVinfected patients, the following additional parameters were collected: risk activity, date of initiation of ART, history of previous opportunistic infection, history of AIDS-defining illness, CD4 þ lymphocyte count, and HIV load at lymphoma diagnosis. Nodal/extranodal definition DLBCL cases were classified as primary nodal and primary extranodal according to a previously reported definition [15] . Lymphomas presenting in extranodal organs with no or only minor lymph node involvement were considered primary extranodal. Lymphomas with clinically dominant lymph node involvement, as well as those presenting in the spleen and Waldeyer's ring, were considered as primary nodal. Bone marrow was considered an extranodal site. Finally, lymphomas with 
Results
Clinical-biological features of patients
The baseline clinical-biological features of the two series of DLBCL studied are summarized in Table 1 . Briefly, HIV-infected patients were younger at the time of DLBCL diagnosis (median 44 years) than HIV-uninfected patients (median 62 years) (P < 0.001) and were predominantly men (81 vs. 52%; P < 0.001). Compared with HIV-uninfected patients, those with HIV-infection showed a higher frequency of B-symptoms (53 vs. 26%; P < 0.001), III and IV Ann Arbor stages (72 vs. 52%; P ¼ 0.011), ECOG score at least 2 (51 vs. 26%; P < 0.001), and higher LDH levels at diagnosis (61 vs. 45%; P ¼ 0.057). The frequency of an intermediate-high IPI score, extranodal involvement in two or more areas, bulky disease, bone marrow, and CNS involvement and extranodal involvement were similar in both series. Moreover, both HIV-infected and HIV-uninfected patients had a higher frequency of primary nodal than extranodal presentation according to the definition applied.
Two thirds of HIV-infected patients were on cART at the time of DLBCL diagnosis, whereas cART was started at the time of lymphoma diagnosis in the remaining patients (Tables 1 and 2) . Compared with cART-naive patients, 
Results of treatment and clinical outcome
All HIV-uninfected patients and 80 HIV-infected patients (one was withdrawn early) were evaluable for response to R-CHOP treatment. Response to R-CHOP was slightly worse, although with not statistical significance, in HIVinfected than in HIV-uninfected patients (CR; 69 vs. 81%, P ¼ 0.071) ( Table 3 ). The relapse rate was similar in both series. At the closure of this study, more HIVuninfected than HIV-infected patients were alive (73 vs. 52%, P ¼ 0.009). The causes of death were different in the two series, although the incidence of deaths related to treatment toxicity was similar (nine out of 38, 24% for HIV-infected vs. five out 23, 22% for HIV-uninfected patients; P ¼ 0.861). Deaths due to lymphoma were less frequent in HIV-infected than in HIV-uninfected patients ( With a median follow-up of 6.5 years (range: 0.1-9.5) for HIV-infected patients and 4.6 years (range: 0.6-13.0) for HIV-uninfected patients, the 5-year OS probability was significantly worse in the former group [56%, 95% confidence interval (45-67%) vs. 74%, 95% confidence interval (64-84%); P ¼ 0.009] (Fig. 1a ). However, no differences were observed in DFS (Fig. 1b) .
HIV-infected patients with DLBCL showed more aggressive features at diagnosis than HIV-uninfected patients and that may explains their poorer response to therapy and outcomes. In order to remove that bias, subgroups of patients with similar tumor burden defined by high IPI scores (3) (4) (5) were analyzed. Comparing these subgroups, CR rate was not significantly different between HIV-infected (N ¼ 33) and HIV-uninfected patients (N ¼ 29) (58 vs. 72%; P ¼ 0.102). Furthermore, the results regarding survival comparing only patients with high tumor burden were similar to those of the whole series; the OS of HIV-infected patients was worse 814 AIDS 2015, Vol 29 No 7 cART, combination antiretroviral therapy. than the OS of HIV-uninfected patients (Fig. 1c ), and the DFS was similar in both groups (Fig. 1d ). Although the extent of the difference in OS between HIV-infected and HIV-uninfected patients was the same in the whole series and in the high tumor burden subgroup, in the latter the difference was not statistically significant. The number of patients included in the high tumor burden subgroup was smaller probably reducing the statistical power of the test.
In HIV-infected patients, an ECOG score at least 2, increased LDH level, IPI score at least 2 and bone marrow involvement were associated with failure to achieve CR, (see Table, Supplemental Digital Content 1, http://links.lww.com/QAD/A663, which discloses the univariate analysis of prognostic factors for CR of HIVinfected patients). On multivariate analysis, only bone marrow involvement and elevated LDH were found to be negative prognostic factors for CR (Table 4 ). In HIVuninfected patients, raised LDH showed a trend for less CR in both univariate (see Table, Supplemental Digital Content 1, http://links.lww.com/QAD/A663, which discloses the univariate analysis of prognostic factors for CR of HIV-uninfected patients) and multivariate analyses ( Table 4 ).
None of the features studied had a prognostic impact on DFS in HIV-infected patients (see Table, Supplemental Digital Content 2, http://links.lww.com/QAD/A664, which discloses univariate analysis of prognostic factors for DFS of HIV-infected patients). In HIV-uninfected patients, bone marrow involvement and an IPI score at least 2 were associated with a shorter DFS (see Table, HIV-infection impact on DLBCL responses to R-CHOP Baptista et al. Multivariate analysis showed that only bone marrow involvement was of prognostic value for DFS (Table 4 ). A history of previous opportunistic infection, prior AIDSdefining illness, IPI score at least 2, bone marrow involvement, and elevated LDH were associated with shorter OS in HIV-infected patients by univariate analysis (see Table, Supplemental Digital Content 2, http:// links.lww.com/QAD/A664, which discloses univariate analysis of prognostic factors for OS of HIV-infected patients). Only a previous history of AIDS and bone marrow involvement were found to be of prognostic value for OS in the multivariate analysis (Table 4 ). In HIV-uninfected patients, male gender, bone marrow involvement, and increased LDH levels tended to have negative impact on OS (see Table, Supplemental Digital Content 2, http://links.lww.com/QAD/A664, which discloses univariate analysis of prognostic factors for OS of HIV-uninfected patients), but in the multivariate analysis only bone marrow involvement tended to predict a shorter OS (Table 4 ).
Discussion
The results of this study show that in the cART era DLBCL in HIV-infected patients still show more aggressive features than those arising in the HIVuninfected population and have a poorer OS, despite having a similar DFS. The main reason for the difference in survival was the higher frequency of deaths not related to lymphoma in HIV-infected patients.
In agreement with other studies, HIV-infected patients with DLBCL in our series showed a poorer general status and a higher frequency of B-symptoms and advanced stages than HIV-uninfected patients [6, 17] . Moreover, patients with HIV-related DLBCL were younger and more frequently men, reflecting the demographic groups currently with the highest incidence of HIV-infection [3] . However, the frequency of extranodal involvement, especially bone marrow and CNS, were similar in both groups of patients. These results contrast in part with those from a recent study that reported a higher frequency of involvement of two or more extranodal sites in HIVrelated DLBCL [17] . Importantly, our results point to a reduction of CNS involvement in systemic HIV-related DLBCL, which is now equalizing that of DLBCL in the general population, supporting prior studies [17, 18] .
Overall, data show that in the cART era the frequency of certain aggressive features of HIV-related DLBCL has decreased, but others still persist. Even though all HIVinfected patients with DLBCL analyzed in the present study were diagnosed in the cART era, some were not treated with cART before the diagnosis of lymphoma. We did not find differences in the characteristics of lymphoma at presentation between the subgroups of HIV-infected patients previously and not-previously treated with cART, but more patients previously treated with cART presented an undetectable HIV load, history of opportunistic infection, and AIDS-defining illness. These results are in agreement with a report from the Center for AIDS Research Network of Integrated Clinical Systems [3] .
The results of R-CHOP treatment were slightly different between HIV-infected and HIV-uninfected patients. The rates of CR in HIV-infected and HIV-uninfected patients were in agreement with other studies [19] [20] [21] [22] [23] . When comparing both series, our results were slightly different from those by Coutinho et al. [17] , most probably because the CR rate of their HIV-uninfected cohort (73%) was lower than that previously reported [21] [22] [23] . Of note, in our study, the HIV-related DLBCL series showed a higher incidence of lymphoma aggressive features, with some features such as high LDH levels being identified by multivariate analysis as poor prognostic factors for attaining CR in both series of patients. Interestingly, none of the HIV-related features had an impact on the achievement of CR in the univariate analysis, not even CD4 þ cell counts below 50/ml (data not shown) as reported by Kaplan et al. [20] . The above-mentioned studies and the similar rates of CR observed in the subgroups of patients with high tumor burden sustain that the trend of the whole series of HIV-infected patients to have worse rates of CR to R-CHOP than HIVuninfected patients could be attributed to the presence 816 AIDS 2015, Vol 29 No 7 of more aggressive features inherent to lymphoma. Importantly, the frequencies of deaths during treatment were in line with previous studies, 11% in HIV-infected [19, 20] and 6% in HIV-uninfected series [21, 22] , and they were not statistically different between the two series.
Our results demonstrate the effectiveness of R-CHOP with concomitant cART in the treatment of HIV-related DLBCL, but causes of death other than lymphoma contribute to the worse outcome of HIV-related DLBCL. At the closure of this study, there were more global deaths among HIV-infected patients (48%) than HIV-uninfected (27%). The frequency of deaths related to treatment toxicity was similar in both DLBCL series, but 22% of the deaths occurring in HIV-infected patients were due to second cancers and to HIV-related complications, causes of death not observed in the HIV-uninfected population. The OS of HIV-infected patients was shorter than that of HIV-uninfected patients (5-year OS 56 vs. 74%, respectively), and the results of OS in our HIV-infected and HIV-uninfected series are in agreement with previous studies [19] [20] [21] [22] [23] [24] [25] [26] [27] . However, our results contrast with those by Coutinho et al. [17] who reported an unexpected better OS for HIV-infected patients compared with HIV-uninfected. An elevated LDH and an IPI score at least 2 were bad prognostic factors for OS on univariate analyses in both series of patients, and bone marrow involvement was indicative of poorer prognosis in univariate analyses in HIV-uninfected patients and retained its bad prognostic importance in the multivariate analysis of HIV-infected patients. These observations are in agreement with a recent analysis focused on the negative impact of bone marrow involvement in the outcome of DLBCL treated with R-CHOP [28] . Although 21% of the patients with HIVrelated DLBCL presented CD4 þ cell counts below 50/ml (data not shown) only a history of opportunistic infection and of AIDS-defining illness were found to be negative prognostic factors for OS, the latter being the strongest negative prognostic factor for OS in the multivariate analysis. The negative impact of AIDS-defining illness on OS can probably be attributed to the lasting severe imbalance of CD4 þ memory T-cell subpopulations observed in these patients [29] . Remarkably, DFS was similar in both series of patients and although HIV-infected patients had more aggressive features than HIV-uninfected patients, in the former, these did not influence DFS. The results confined to the subgroup of patients with high tumor burden (IPI scores 3-5) showed that HIV-infected patients still present worse OS than HIV-uninfected, but that DFS and CR rates are similar which further supports the negative impact of HIV-infection on the overall outcome of patients but not on the response to therapy.
Even though HIV-related DLBCL data were collected within a clinical trial with its inherent accuracy, HIVuninfected DLBCL data were collected retrospectively but according to the criteria used in the trial. In both instances, only patients receiving R-CHOP as a first-line treatment were selected; hence, the results concerning DLBCL features should be interpreted within the context of patients in whom R-CHOP treatment was appropriate. Nonetheless, our findings are strengthened by the results of other HIV-infected and HIV-uninfected DLBCL series [19] [20] [21] [22] [23] [24] [25] [26] [27] .
In summary, in the cARTera, DLBCL presenting in HIVinfected patients continues to have more aggressive features than those in an HIV-negative population. History of AIDS-defining illness along with the high number of deaths unrelated to lymphoma are factors responsible for the worse prognosis of HIV-related DLBCL. However, HIV-infected and HIV-uninfected patients have similar DFS and when matched for high tumor burden show similar CR rates, demonstrating the effectiveness of R-CHOP and concomitant cART in the treatment of HIV-related DLBCL. Early control of HIVinfection to prevent AIDS-defining illnesses before the diagnosis of lymphoma, as well as early cancer detection, may improve the prognosis of HIV-related DLBCL, achieving a similar OS to that of DLBCL in the general population.
